Cogent Biosciences, Inc. COGT Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cogent Biosciences, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cogent Biosciences, Inc.'s stock-based comp?
- Cogent Biosciences, Inc. (COGT) reported stock-based comp of $16.91M in Q1 2026.
- How has Cogent Biosciences, Inc.'s stock-based comp changed year-over-year?
- Cogent Biosciences, Inc.'s stock-based comp increased by 68.9% year-over-year, from $10.01M to $16.91M.
- What is the long-term trend for Cogent Biosciences, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Cogent Biosciences, Inc.'s stock-based comp has grown at a 40.9% compound annual growth rate (CAGR), from $11.69M to $46.08M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.